WO1996030038A1 - Facteur de croissance peptidique ayant une activite induisant l'epiderme - Google Patents

Facteur de croissance peptidique ayant une activite induisant l'epiderme Download PDF

Info

Publication number
WO1996030038A1
WO1996030038A1 PCT/US1996/004326 US9604326W WO9630038A1 WO 1996030038 A1 WO1996030038 A1 WO 1996030038A1 US 9604326 W US9604326 W US 9604326W WO 9630038 A1 WO9630038 A1 WO 9630038A1
Authority
WO
WIPO (PCT)
Prior art keywords
tgf
gene product
bmp
cells
gene
Prior art date
Application number
PCT/US1996/004326
Other languages
English (en)
Inventor
Ali Hemmati-Brivanlou
Paul Wilson
Original Assignee
The Rockefeller University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Rockefeller University filed Critical The Rockefeller University
Priority to EP96910644A priority Critical patent/EP0820298A1/fr
Priority to AU53783/96A priority patent/AU5378396A/en
Publication of WO1996030038A1 publication Critical patent/WO1996030038A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

Definitions

  • This invention relates generally to gene products of the TGF- / 3 gene family, to methods and compositions utilizing such factors, and to the antibodies reactive toward them, in assays and for diagnosing, preventing and/or treating cellular debilitation, derangement or dysfunction.
  • follistatin was expressed in the organizer region in Xenopus, from where it could act to block activin signaling in the dorsal ectoderm and thus permit neural tissue to form, naturally suggested follistatin as an endogenous neural inducer. Although these were enticing speculations, there was no direct evidence that activin could act to specify epidermis, or that such an inducer existed at all.
  • the BMPs are a set of closely related proteins that form a subgroup within the larger TGF-j8 superfamily of secreted growth factors that also includes activin and the TGF's proper.
  • the BMPs First purified from bone as activities capable of promoting bone regrowth, the BMPs have more recently been found in early vertebrate embryos, where they appear to play a variety of roles.
  • BMPs 2 and 4 are capable of inducing ventral mesoderm, as well as ventralizing mesoderm induced by activin.
  • TGF- ⁇ Transforming Growth Factor- ⁇
  • TGF- ⁇ 1 in combination with basic fibroblast growth factor (Kimelman and Kirschner, 1987), TGF- ⁇ 2 alone (Rosa et al. , 1988) and activin A (XTC-MIF) (Asashima et al., 1990); Smith et al. , 1990; van den Eijnden-Van Raaji et al., 1990) can induce mesodermal differentiation and specific gene expression in isolated Xenopus animal caps which would otherwise form ectoderm.
  • TGF- ⁇ 1 , - ⁇ 2, and - ⁇ 3 transcripts and/or protein have revealed temporal and spatial patterns of expression consistent with many roles for TGF- ⁇ -related genes in murine embryogenesis (Heine et al. , 1987; Lehnert and Akhurst, 1988; Pelton et al. , 1989, 1990).
  • a group of the TGF- ⁇ gene family, whose members show greatest homology to the Drosophila Decapentaplegic (dpp) (Padgett et al. , 1987) and Xenopus Vg-1 (Weeks and Melton, 1988) genes includes the Bone Morphogenetic Proteins (BMP) 2,3
  • Vgr-1 mouse oocytes, suprabasal layers of keratinized epithelium and hypertrophic cartilage in developing bone (Lyons et al. , 1989b).
  • BMP-2 A different pattern of expression is seen for BMP-2, which is localized to the apical ectodermal ridge of limb buds, development hair and whisker follicles, condensing, precartilaginous mesenchyme and the myogenic layer of the atrioventricular cushions of the developing heart, as well as other areas undergoing morphogenesis during murine development (Lyons et al. , 1989b, 1990).
  • the original BMP-4 CDNA (formerly called BMP-2b) was isolated because of its homology to BMP-2 (Wozney et al., 1988).
  • This cDNA encodes a protein whose carboxy terminus (TGF- ⁇ conserved region) shows 92% amino acid identity to the corresponding region of BMP-2.
  • the carboxy termini of BMP-2 and BMP-4 are more closely related to the corresponding region of Drosophila dpp protein than to any other known member of the TGF- ⁇ gene family.
  • BMP-4 transcripts are localized to specific regions of the developing mouse that are undergoing morphogenesis. These include cells of newly formed mesoderm in the posterior primitive streak region of 8.5 days, p.c. embryos, as well as cell types involved in craniofacial development, limb bud formation, cardiac development and neuroepithelium associated with pituitary development. In some of these tissues, it appears that the distribution of BMP-4 transcripts overlaps that of BMP-2. In other cases, the expression patterns of the two genes are different. In the central nervous system (CNS), the pattern of BMP-4 expression is also distinct from that of Vgr-1. Vgr-1 transcripts have been localized in the roof plate and in neuroepithelium adjacent to the floor plate within the developing CNS.
  • BMP-4 is expressed both in the AER at 10.5 days p.c. and in the mesenchyme, apparently in an anterior-posterior and distal-proximal gradient (Fig. 7). The possibility therefore exists that BMP-2 and BMP-4 cooperate to influence early limb development. Moreover, heterodimers of BMP-2 and BMP-4 could be formed within the AER. TGF- ⁇ -related growth factors have been shown to have clearly different activities when acting as a homodimer or heterodimer. For example, inhibin ⁇ homodimers selectively stimulate FSH release in the pituitary gland, while inhibin ⁇ / ⁇ heterodimers inhibit such secretion (Hsueh et al. , 1987).
  • BMP-4 could therefore have differing effects if it is a homodimer in the mesenchyme or complexed with BMP-2 in the AER.
  • BMP-4 is apparently expressed in a gradient in the mesenchyme invites comparison with the gradients detected for homeobox-containing genes such as members of the Hox 5 cluster (Dolle et al. , 1989a) and Xlhbox 1/Hox 3.3 (Oliver et al., 1988).
  • homeobox-containing genes such as members of the Hox 5 cluster (Dolle et al. , 1989a) and Xlhbox 1/Hox 3.3 (Oliver et al., 1988).
  • BMP-4 expression in the mesenchyme is transient, since no hybridization signal is found in the mesenchyme of stage 2 follicles. From this localization pattern, BMP-4 could be acting as a signalling molecule, instructing the overlying ectoderm. Consistent with this view, mesenchymal condensations can induce hair follicle formation when transplanted under previously hairless epithelium (Kollar, 1980). The expression of BMP-4 in facial regions of the early mouse embryo suggests a role of the gene in craniofacial mo ⁇ hogenesis. Expression in the early otic vesicle also raises the possibility that BMP-4 is involved in development of the inner ear.
  • BMP-4 expression is often coordinated in a temporal and spatial manner with expression of other members of the TGF- ⁇ gene family, particularly the closely related gene, BMP-2. While the full significance of these patterns must await studies with the purified proteins and localization of the cellular receptors for each molecule, they nevertheless strongly suggest that members of the TGF- ⁇ family function in inductive tissues interact during the establishment of several specialized organ systems within the developing embryo.
  • BMPs 2-7 form a unique subfamily within the TGF-jS gene family (Wozney (1993) "Bone Mo ⁇ hogenetic Proteins and Their Gene Expression, " in Cellular and Molecular Biology of Bone, M.
  • the BMPs act as differentiation factors, causing induction and increased expression of multiple differentiated phenotypes in mesenchymal cells.
  • the BMPs are also involved in a variety of developmental processes including (1) the formation of the skeleton; (2) the development of organ and tissue systems that form via mesenchymal-epithelial interactions; and (3) and possibly the delivery or inte ⁇ retation of positional information (Wozney, 1993).
  • BMP-2 and BMP-4 are disclosed in U.S. Patent Nos. 5,013,649 and 5, 166,058, respectively, which are hereby inco ⁇ orated by reference in their entirety.
  • a comparison of the amino acid sequences of the human BMPs indicates that significant amino acid identity exists among all the BMPs in the carboxy terminal region of the proteins. This region contains seven cysteine residues, whose presence and relative positions are conserved among all reported members of the TGF- / 3 superfamily.
  • BMP-2 and BMP-4 are 92 % identical in the seven- cysteine region. All of BMPs 2-7 contain hydrophobic secretory leader sequences and substantial propeptide regions.
  • the mature portion of each molecule resides in the carboxy terminus of the prepropeptide and includes the seven-cysteine domain.
  • the amino-terminal domains of the mature BMPs are basic, processing occurring at the consensus sequence of Arg-X-X-Arg.
  • the BMPs are glycosylated, BMP-4 having two N-linked glycosylation sites.
  • BMP-4 is localized to chromosome 14, and may be a candidate for the pugnose locus, which results in abnormalities in skull bone development (Wozney, 1993).
  • Each mature, active BMP is a dimeric molecule containing two of these polypeptides. Potential also exists for formation of heterodimeric forms of the BMPs, which may possess different specific activities, receptor binding characteristics, or entirely novel activities relative to the homodimer ic forms (Wozney, 1993). BMP-2, BMP-4, BMP-5, BMP-6 and BMP-7 all induce some alkaline phosphatase expression in W-20-17 cells but vary in specific activity. The difference in activity between the less active BMP-2 and more active BMP-4 can be obviated by removal of their amino-terminal domains with trypsin, suggesting a role for this domain in receptor binding or ligand presentation.
  • Specific embryonic tissue with "organizing" activity that exists in amniotes include Hensen's node in birds and the node in mammals that can give rise to a secondary axis when transplanted to an ectopic site of host embryos (Beddington, 1994; Waddington and Schmidt, 1933). Hensen's node from chick embryos can induce neural tissue when recombined with Xenopus ectoderm (Kintner and Dodd, 1991). These similarities suggest that factors involved in these types of inductive interactions may be conserved among different vertebrate species.
  • TGF-/3 family members have been implicated in the differentiation processes of P19 cells (reviewed in Mummery and van den Eijnden-van Raaij, 1993). There is evidence that activin promotes proliferation of undifferentiated PI 9 cells (Hashimoto et al. , 1990; Schubert et al. , 1990). Activin has also been shown to inhibit neural differentiation induced by RA (Hashimoto et al. , 1990; van den Eijnden-van Raaij et al. , 1991), implicating activin as a neural inhibitor in mammalian cells.
  • P19 cells also express both the type I and the type II activin receptors (Kondo et al. , 1989). Collectively, these data support the conclusion that TGF-j8 signaling in P19 cells is intact and suggest a role of TGF- / 3 signaling in the neural differentiation of mammalian cells.
  • Neural inducers have long been sought by exposing explanted ectoderm to candidate substances or extracts.
  • ectoderm dispersed for several hours adopts a neural fate (see above), it should be possible to add factors back to such a culture system in an effort to restore the epidermal specification of the intact cap.
  • Identification of an epidermal inducer in this way would lend strong support to the default neural model, by showing that epidermis can in fact be an induced tissue. Moreover, such a finding could guide work on neural induction, focussing attention on antagonists of the epidermal inducer.
  • BMP-4 has been reported to mediate cell death in the developing hindbrain later in development, no role for BMPs in the earliest development of the ectoderm had been suggested until the present invention.
  • a major object of the present invention is to provide a method of preventing and/or treating cellular debilitations, derangements and/or dysfunctions and/or other disease states in mammals, including administering to a mammal a therapeutically effective amount of a material selected from the group consisting of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof, an agent capable of promoting the production and/or activity of the gene product of a member of the TGF- ⁇ gene family, an agent capable of mimicking the activity of the gene product of a member of the TGF- 3 gene family, an agent capable of inhibiting the production of the gene product of a member of the TGF- ⁇ gene family, and mixtures thereof, or a specific binding partner thereto, wherein the gene product of a member of the TGF-3 gene family induces formation of epidermis.
  • a material selected from the group consisting of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof, an agent capable of promoting the production
  • Another object of the invention is to provide a method for producing artificial skin, including adding an amount of a gene product of a member of a TGF-j ⁇ gene family or active fragment thereof sufficient to form epidermis to a culture of cells which are induced to form epidermis.
  • Still another object of the invention is to provide a method of inhibiting neural induction, including administering to a mammal an amount sufficient to inhibit neural induction of a material selected from the group consisting of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof, an agent capable of promoting the production and/or activity of the gene product of a member of the TGF-jS gene family, an agent capable of mimicking the activity of the gene product of a member of the TGF- ⁇ gene family, an agent capable of inhibiting the production of the gene product of a member of the TGF- ⁇ gene family, and mixtures thereof, or a specific binding partner thereto.
  • a material selected from the group consisting of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof, an agent capable of promoting the production and/or activity of the gene product of a member of the TGF-jS gene family, an agent capable of mimicking the activity of the gene product of a member of the TGF- ⁇ gene family, an agent
  • Yet another object of the invention is to provide a method of inducing epidermis formation, including administering to a mammal an amount sufficient to induce epidermis formation of a material selected from the group consisting of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof, an agent capable of promoting the production and/or activity of the gene product of a member of the TGF- ⁇ gene family, an agent capable of mimicking the activity of the gene product of a member of the TGF- ⁇ gene family, an agent capable of inhibiting the production of the gene product of a member of the TGF- ⁇ gene family, and mixtures thereof, or a specific binding partner thereto.
  • a further object of the invention is to provide a method for identifying a compound which is an antagonist of a gene product of a member of a TGF- ⁇ gene family or active fragment thereof for inducing epidermis including the steps of:
  • B detecting whether the level of epidermis induction by the gene product of a member of a TGF- ⁇ gene family and a candidate is decreased relative to the level of epidermis induction in a control biological sample; wherein a decrease in the level of epidermis induction by the gene product of a member of a TGF- ⁇ gene family indicates that the candidate is an antagonist of the epidermis inducing activity of the gene product of a member of a TGF- ⁇ gene family.
  • Another object of the invention is to provide a method for inducing expression of an epidermal cell surface marker in epidermal progenitor cells, including contacting said cells with an amount of a gene product of a TGF- ⁇ gene family or active fragment thereof sufficient to induce expression of the cell surface marker.
  • the present invention features a gene product of a member of the TGF- ⁇ gene family, which can be used to induce the formation of epidermis, and suppress autoneuralization of progenitor cells.
  • the invention relates to bone mo ⁇ hogenesis protein-4 (BMP-4), and its use in treating diseases or debilitations relating to the skin and nervous system.
  • BMP-4 but not activin, restores epidermal differentiation to dispersed gastrula ectoderm.
  • BMP-4 can also be used to produce artificial skin for the testing of drugs, cosmetics and other medicaments, and to induce or suppress the expression of certain cell surface molecules which are associated with skin and neural tissue, respectively.
  • the invention relates to antagonists of BMP-4, which can act to reverse or diminish the action of BMP-4 under certain circumstances.
  • FIG. 1 Prolonged dispersal neuralizes late blastula ectoderm. Late stage 9 animal caps were disaggregated in calcium and magnesium-free media. Cells were reaggregated immediately (0 hours), or after 1-5 hours of dispersed culture. Reaggregates were cultured to the end of neurulation, when RNA was extracted for RT-PCR. Ectoderm subjected to dispersal and immediate reaggregation differentiates as epidermis, as do intact animal caps, expressing the epidermis- specific cytokeratin. The general neural marker NCAM is not present. Dispersal for 2 hours or less has no effect.
  • RNA extraction and RT-PCR were also as in ref -, with the single modification that random hexamers rather than oligo dT were used to prime reverse transcription.
  • B Autoneuralization by prolonged dispersion does not require secondary cell-cell interactions. RNA was extracted from dispersed animal cap ectoderm, either reaggregated after 0, 4, or 7 hours, or maintained in dispersion until stage 15.
  • Activin does not induce epidermis. Late blastula animal caps were disaggregated, cultured for 4 hours in various concentrations of activin, and reaggregated. RNA was extracted for RT-PCR at the end of neurulation. In the absence of activin and at low activin concentration dispersed cells are neuralized, expressing NCAM (lanes 2-4). At higher activin concentrations mesoderm is induced, as shown by the presence of Xbra message. At no concentration is epidermis formed. Cells reaggregated immediately after dispersal go on to express epidermal keratin (lane 1), as do intact caps, which also express Xbra when cultured in activin.
  • the activin used in this experiment is partially purified supernatant from P388D1 cells, units are arbitrary.
  • Dispersed cells were cultured in IX calcium and magnesium-free MBSH with 0.5 mg/ml USA.
  • Figure 3. BMP-4 induces epidermis in dispersed ectoderm. Dissociated stage 9 animal cap cells as well as intact caps were incubated for 4 hours with or without BMP-4 protein. In the absence of added factor, dispersed cells express NCAM after reaggregation and culture to stage 18 (lanes 2). In contrast, dispersed cells exposed to BMP-4 at all concentrations tried in this experiment strongly expressed the epidermis-specific keratin (3-6). NCAM expression is suppressed. A high concentration of BMP-4 induces the posterior mesodermal marker Xbra in intact caps (lane 9). Recombinant human BMP-4 was obtained from Genetics Institute.
  • a dominant-negative activin receptor can block the induction of epidermis by BMP-4.
  • Animal caps from embryos previously injected with RNA encoding the truncated activin receptor ( ⁇ 1AR1) and uninjected control embryos were cut and dissociated at the late blastula stage. Dispersed blastomeres were incubated for 4 hours in the presence or absence of 50 ng/ml BMP-4 protein, reaggregated, and cultured to late neurula stage.
  • BMP-4 suppresses neural development and induces epidermis in dispersed ectoderm from control embryos (lane 3). but not in cells from injected embryos, which continue to strongly express NCAM (lane 6).
  • RNA for injection was synthesized in vitro by standard methods; a total of 2 ng of RNA was injected into the animal hemisphere of two cell stage embryos. The construction of ⁇ 1AR1 was described previously.
  • FIG. 5 Follistatin protein cannot block the epidermalizing activity of BMP-4. Dispersed late blastula ectoderm was cultured in media containing 50 ng/ml BMP- 4 protein alone, 1 ⁇ g/ml follistatin protein alone, both proteins at these concentrations, or in the absence of either factor.
  • A Prolonged dispersal results leads reaggregated ectoderm to express NCAM (lane 2); exposure to follistatin alone has no effect (lane 3).
  • BMP-4 suppresses NCAM and induces epidermal keratin (lane 4). Follistatin protein, even at a high dose, is unable to block epidermalization by BMP-4 (lane 5).
  • Figure 5B demonstrates that the follistatin protein used in this experiment was active, completely blocking mesoderm induction by activin in intact caps, as assayed by expression of muscle actin.
  • the dose required to block activin here was 10 ng/ml, 100-fold less than the dose used on dispersed cells.
  • Human recombinant short-form follistatin protein was obtained from NIH.
  • FIG. 6 Neural induction in PI 9 cells transfected with the truncated Xenopus activin type II receptor.
  • P19 cells were stably transfected with the control plasmid, pcDNA3 (A and B) or ⁇ lXARlmyc (C and D).
  • Immunofluorescence using a monoclonal antibody to NF-160 as a marker of neural differentiation with a Texas-red conjugated secondary antibody (A and C) and the corresponding DIC micrographs (B and D) are shown. Neural induction was observed in the P19 cell line which was transfected with the truncated receptor.
  • FIG. 7 Colocalization of the ⁇ lXARlmyc receptor with neural antigen NF200.
  • the P19 ⁇ lXARlmyc cell line was grown on chamber slides and was analyzed for expression of the neural marker NF-200 using a polyclonal antibody and the truncated activin receptor with the yc tag as a marker using the monoclonal antibody, 9E10.
  • Confocal micrographs are shown illustrating indirect immunofluorescence of NF-200 with a fluorescein conjugated secondary antibody (A), the myc tag with a Texas red conjugated secondary antibody (B) and double immunofluorescence of both NF-200 and myc (C).
  • the myc labeling indicates that the truncated activin receptor is expressed in this cell line. In addition, high levels of myc labeling is coincident with neural differentiation.
  • FIG. 8 Time course of neural induction in P19 ⁇ lXARlmyc.
  • the cell line P19 ⁇ lXARlmyc and a control cell line P19pcDNA3 were plated at low density and neural ization was followed over 7 days using expression of the NF-160 as a marker of neural differentiation.
  • the number of cells expressing the neural NF-160 antigen was calculated as a percentage of the total number of cells present in a randomly chosen field of view. The results presented represent averages of approximately 15 fields of view from 2 separate experiments. No neurons were observed in P19pcDNA3 (squares) during the 7 days. In P19 ⁇ lXARlmyc (triangles) differentiated neurons were not apparent until the cells had neared confluence which occurred at about day 4.
  • BMP4 inhibits neuralization of P19 cells by retinoic acid.
  • P19 cells were grown for 4 days on a solid surface in control media (A and B) or media supplemented with 3.6nM BMP4 (C and D), 0.5mM RA (E and F), 0.5mM retinoic acid and 0.36nM BMP4 (G and H) or 0.5mM RA and 3.6nM BMP4 (I and J), followed by 2 days in control media.
  • Neuralization was assessed by indirect immunofluorescence for expression of NF-160 (A, C, E, G, and I). The corresponding DIC pictures are shown (B, D, F, H and J).
  • BMP4 inhibits RA induced neural differentiation at concentrations as low as 0.36nM. This inhibition is more severe when 3.6nM BMP4 is used to challenge RA.
  • FIG. 10 Induction of keratins by BMP4 in P19 cells.
  • PI 9 cells were grown on solid surfaces for 4 days in control media (A and B) or in media supplemented with 3.6nM BMP4 (C-H) followed by 2 days in control media.
  • Epithelial differentiation was assessed by indirect immunofluorescence for expression of keratin using a mixture of monoclonal antibodies (A, C, E and G). The corresponding DIC pictures are shown (B, D, F and H). Cultures incubated with BMP4 showed keratin expression.
  • Panels C, E and G demonstrate the different cell mo ⁇ hologies observed in keratin expressing cells.
  • FIG. 1 Construct pSP64TS.
  • A A schematic of the pSP64T construct (3kb) containing a procaryotic promoter (SP6) and a 30bp insert. The construct provides additional cloning sites, including a blunt end site and stop codons at all three reading frames downstream of the Bglll, EcoRV and the Spe l site.
  • the host strain HBlOl is ampicilin-sensitive, the plasmid confers ampicilin-resistam.
  • B The partial nucleotide sequence of the pSP64TS construct between the Hndlll site and the EcoRl site showing the 30 bp insert (heavy underlining) in the sense orientation, relative to the promoter.
  • the present invention relates to a gene product of a member of the TGF- ⁇ gene family, and preferably to BMP-4, a peptide growth factor related to activin, which can strongly suppress autoneuralization and induce epidermis in dispersed cells.
  • BMP-4 a peptide growth factor related to activin
  • This induction is blocked by a dominant-negative form of the activin receptor, suggesting that the previously reported neuralizing activity of the truncated receptor in embryos may result from antagonizing endogenous BMP-4.
  • BMP-4 is expressed in the Xenopus ectoderm at the stage when the decision between epidermal and neural fates is made, this factor appears to be an endogenous neural inhibitor and epidermal inducer, the first reported in any vertebrate.
  • the discovery of an epidermal inducer lends considerable support to the default model of neural specification.
  • proteins displaying substantially equivalent or altered activity are likewise contemplated. These modifications may be deliberate, for example, such as modifications obtained through site-directed mutagenesis, or may be accidental, such as those obtained through mutations in hosts that are producers of the complex or its named subumts. Also, the terms “bone morphogenesis protein”, “bone mo ⁇ hogenesis factor”, “BMP-4”, “BMP-2B, “morphogenesis factor” , and “morphogenesis factor prote ⁇ n(s)” are intended to include within their scope proteins specifically recited herein as well as all substantially homologous analogs and allelic variations.
  • a “rephcon” is any genetic element (e.g. , plasmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo, i e , capable of replication under its own control.
  • a “vector” is a rephcon, such as a plasmid, phage or cosmid. to which another DNA segment may be attached so as to bring about the replication ot the attached segment.
  • a “cassette” refers to a segment of DNA that can be inserted into a vector at specific restriction sites. The segment of DNA encodes a polypeptide of interest, and the cassette and restriction sites are designed to ensure insertion of the cassette in the proper reading frame for transcription and translation.
  • a cell has been "transfected” by exogenous or heterologous DNA when such DNA has been introduced inside the cell.
  • a cell has been "transformed” by exogenous or heterologous DNA when the transfected DNA effects a phenotypic change.
  • the transforming DNA should be integrated (covalently linked) into chromosomal DNA making up the genome of the cell.
  • Heterologous DNA refers to DNA not naturally located in the cell, or in a chromosomal site of the cell.
  • the heterologous DNA includes a gene foreign to the cell.
  • a "clone” is a population of cells derived from a single cell or common ancestor by mitosis.
  • nucleic acid molecule refers to the phosphate ester polymeric form of ribonucleosides (adenosine, guanosine, undine or cytidine; "RNA molecules”) or deoxy ⁇ bonucleosides (deoxyadenosine, deoxyguanosine, deoxythymidine, or deoxycytidine; "DNA molecules”) in either single stranded form, or a double- stranded hehx. Double stranded DNA-DNA, DNA-RNA and RNA-RNA helices are possible.
  • nucleic acid molecule refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms.
  • this term includes double- stranded DNA found, inter alia, in linear or circular DNA molecules (e.g. , restriction fragments), plasmids, and chromosomes.
  • sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA (i.e. , the strand having a sequence homologous to the mRNA).
  • a "recombinant DNA molecule” is a DNA molecule that has undergone a molecular biological manipulation.
  • a nucleic acid molecule is "hyb ⁇ dizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single stranded form of the nucleic acid molecule can anneal to the other nucleic acid molecule under the appropriate conditions of temperature and solution ionic strength (see Sambrook et al. , supra).
  • the conditions of temperature and ionic strength determine the "stringency" of the hybridization.
  • low stringency hybridization conditions corresponding to a T m of 55°, can be used, e.g. , 5x SSC, 0.
  • Moderate stringency hybridization conditions correspond to a higher T m , e.g. , 40% formamide, with 5x or 6x SCC.
  • High stringency hybridization conditions correspond to the highest T m , e.g. , 50% formamide, 5x or 6x SCC.
  • Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible
  • the appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of T m for hybrids of nucleic acids having those sequences.
  • the relative stability (corresponding to higher T m ) of nucleic acid hybridizations decreases in the following order: RNA:RNA, DNA:RNA, DNA:DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating T m have been derived (see Sambrook et al.
  • a minimum length tor a hyb ⁇ dizable nucleic acid is at least about 10 nucleotides; more preferably at least about 15 nucleotides; most preferably the length is at least about 20 nucleotides
  • “Homologous recombination” refers to the insertion of a foreign DNA sequence of a vector in a chromosome.
  • the vector targets a specific chromosomal site for homologous recombination.
  • the vector will contain sufficiently long regions of homology to sequences of the chromosome to allow complementary binding and incorporation of the vector into the chromosome. Longer regions of homology, and greater degrees of sequence similarity, may increase the efficiency of homologous recombination.
  • a DNA "coding sequence” is a double-stranded DNA sequence which is transcribed and translated into a polypeptide in a cell in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxyl) terminus.
  • a coding sequence can include, but is not limited to, prokaryotic sequences, cDNA from eukaryotic mRNA, genomic DNA sequences from eukaryotic (e.g. , mammalian) DNA, and even synthetic DNA sequences. If the coding sequence is intended for expression in a eukaryotic cell, a polyadenylation signal and transcription termination sequence will usually be located 3' to the coding sequence.
  • Transcriptional and translational control sequences are DNA regulatory sequences, such as promoters, enhancers, terminators, and the like, that provide for the expression of a coding sequence in a host cell.
  • polyadenylation signals are control sequences.
  • a “promoter sequence” is a DNA regulatory region capable of binding RNA polymerase in a cell and initiating transcription of a downstream (3' direction) coding sequence.
  • the promoter sequence is bounded at its 3' terminus by the transcription initiation site and extends upstream (5' direction) to include the minimum number of bases or elements necessary to initiate transcription at levels detectable above background.
  • a transcription initiation site (conveniently defined for example, by mapping with nuclease SI), as well as protein binding domains (consensus sequences) responsible for the binding of RNA polymerase.
  • a coding sequence is "under the control" of transcriptional and translational control sequences in a cell when RNA polymerase transcribes the coding sequence into mRNA. which is then trans-RNA spliced and translated into the protein encoded by the coding sequence.
  • a “signal sequence” is included at the beginning of the coding sequence of a protein to be expressed on the surface of a cell. This sequence encodes a signal peptide, N-terminal to the mature polypeptide, that directs the host cell to translocate the polypeptide.
  • the term "translocation signal sequence” is used herein to refer to this sort of signal sequence. Translocation signal sequences can be found associated with a variety of proteins native to eukaryotes and prokaryotes, and are often functional in both types of organisms.
  • oligonucleotide as used herein in referring to the probe of the present invention, is defined as a molecule comprised of two or more ribonucleotides or deoxyribonucleotides, preferably more than three. Its exact size will depend upon many factors which, in turn, depend upon the ultimate function and use of the oligonucleotide.
  • nucleotide probe refers to an oligonucleotide of at least about 9 bases, which has a sequence corresponding to a portion of the DNA coding for a protein of the TGF- ⁇ gene family.
  • sequence homology in all its grammatical forms refers to the relationship between proteins that possess a “common evolutionary origin, "including proteins from superfamilies (e.g. , the immunoglobulin superfamily) and homologous proteins from different species (e.g. , myosin light chain, etc.) (Reeck et al. , 1987, Cell 50:667).
  • sequence similarity in all its grammatical forms refers to the degree of identity or correspondence between nucleic acid or amino acid sequences of proteins that do not share a common evolutionary origin (see Reeck et al., supra).
  • Two DNA sequences are "substantially homologous” or “substantially similar” when at least about 75 % (preferably at least about 80% , and most preferably at least about 90 or 95 %) of the nucleotides match over the defined length of the DNA sequences. Sequences that are substantially homologous can be identified by comparing the sequences using standard software available in sequence data banks, or in a Southern hybridization experiment under, for example, stringent conditions as defined for that particular system. Defining appropriate hybridization conditions is within the skill of the art. See, e.g. , Maniatis et al. , supra; DNA Cloning, Vols. I & II, supra; Nucleic Acid Hybridization, supra.
  • two amino acid sequences are “substantially homologous” or “substantially similar” when greater than 70% of the amino acids are identical, or functionally identical.
  • the similar or homologous sequences are identified by alignment using, for example, the GCG (Genetics Computer Group, Program Manual for the GCG Package, Version 7, Madison, Wisconsin) pileup program.
  • corresponding to is used herein to refer to similar or homologous sequences, whether the exact position is identical or different from the molecule to which the similarity or homology is measured. For example, as demonstrated in Wozney, 1993, infra, the sequences of the BMP proteins can be aligned, and the corresponding amino acid residues determined, despite the deletion of amino acid residues at some positions in one BMP protein compared to another. Thus, the term “corresponding to” refers to the sequence similarity, and not the numbering of the amino acid residues or nucleotide bases.
  • an “antibody” is any immunoglobulin, including antibodies and fragments thereof, that binds a specific epitope.
  • the term encompasses polyclonal, monoclonal, and chimeric antibodies, the last mentioned described in further detail in U.S. Patent Nos. 4,816,397 and 4,816,567.
  • An “antibody combining site” or “antigen recognition site” is that structural portion of an antibody molecule comprised of heavy and light chain variable and hypervariable regions that specifically binds antigen.
  • the phrase "antibody molecule” in its various grammatical forms as used herein contemplates both an intact immunoglobulin molecule and an immunologically active portion of an immunoglobulin molecule.
  • Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules and those portions of an immunoglobulin molecule that contains the paratope, including those portions known in the art as Fab, Fab', F(ab') 2 and F(v), which portions are preferred for use in the therapeutic methods described herein.
  • the phrase "monoclonal antibody” in its various grammatical forms refers to an antibody having only one species of antibody combining site capable of immunoreacting with a particular antigen. A monoclonal antibody thus typically displays a single binding affinity for any antigen with which it immunoreacts.
  • a monoclonal antibody may therefore contain an antibody molecule having a plurality of antibody combining sites, each immunospecific for a different antigen; e.g. , a bispecific (chimeric) monoclonal antibody.
  • a molecule is "antigenic" when it is capable of specifically interacting with an antigen recognition molecule of the immune system, such as an immunoglobulin (antibody) or T cell antigen receptor.
  • An antigenic polypeptide contains at least about 5, and preferably at least about 10, amino acids.
  • An antigenic portion of a molecule can be that portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating the antigenic portion to a carrier molecule for immunization.
  • a molecule that is antigenic need not be itself immunogenic, i.e. , capable of eliciting an immune response without a carrier.
  • adjuvant refers to a compound or mixture that enhances the immune response to an antigen.
  • An adjuvant can serve as a tissue depot that slowly releases the antigen and also as a lymphoid system activator that non-specifically enhances the immune response (Hood et al. , Immunology, Second Ed. , 1984, Benjamin/Cummings: Menlo Park, California, p. 384).
  • a primary challenge with an antigen alone, in the absence of an adjuvant will fail to elicit a humoral or cellular immune response.
  • Adjuvants include, but are not limited to, complete Freund's adjuvant, incomplete Freund's adjuvant, saponin, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil or hydrocarbon emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum.
  • the adjuvant is pharmaceutically acceptable.
  • a composition comprising "A” (where "A” is a single protein, DNA molecule, vector, recombinant host cell, etc.) is substantially free of “B” (where “B” comprises one or more contaminating proteins, DNA molecules, vectors, etc.) when at least about 75 % by weight of the proteins, DNA, vectors (depending on the category of species to which A and B belong) in the composition is "A".
  • "A” comprises at least about 90% by weight of the A+B species in the composition, most preferably at least about 99% by weight. It is also preferred that a composition, which is substantially free of contamination, contain only a single molecular weight species having the activity or characteristic of the species of interest.
  • pharmaceutically acceptable refers to molecular entities and compositions that are physiologically tolerable and do not typically produce an allergic or similar untoward reaction, such as gastric upset, dizziness and the like, when administered to a human.
  • pharmaceutically acceptable means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans.
  • carrier refers to a diluent, adjuvant, excipient, or vehicle with which the compound is administered.
  • Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
  • Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences” by E.W. Martin.
  • terapéuticaally effective amount is used herein to mean an amount sufficient to reduce by at least about 15 percent, preferably by at least 50 percent, more preferably by at least 90 percent, and most preferably prevent, a clinically significant deficit in the activity, function and response of the host. Alternatively, a therapeutically effective amount is sufficient to cause an improvement in a clinically significant condition in the host.
  • biological sample is used herein to refer to a sample containing cells that express or may express a gene product of the TGF- ⁇ gene family. Such cells may be obtained from a subject, or from in vitro culture. The term “biological sample” further extends to an extract of cells from either source.
  • an appropriate antagonist of the binding domain of a gene product of a member of the TGF- ⁇ gene family, and specifically of BMP-4 or another TGF- ⁇ -like protein could be introduced to block the interaction of the BMP-4 protein with its binding site.
  • the antagonists of the TGF- ⁇ -like protein binding, and specifically BMP-4 binding may be prepared in pharmaceutical compositions, with a suitable carrier and at a strength effective for administration by various means to a patient experiencing an adverse medical condition associated specific transcriptional stimulation for the treatment thereof.
  • the pharmaceutical formulation will provide for transmembrane migration of the antagonists, which will be active in the cytoplasm.
  • parenteral techniques such as subcutaneous, intravenous and intraperitoneal injections, catheter izations and the like. Average quantities of the recognition factors or their subunits may vary and in particular should be based upon the recommendations and prescription of a qualified physician or veterinarian.
  • antibodies including both polyclonal and monoclonal antibodies, may possess certain diagnostic or therapeutic (inhibitory) applications and may for example, be utilized for the purpose of detecting and/or measuring conditions such as cellular activation as a result of viral infection, inflammation, or the like.
  • TGF- ⁇ -like protein binding domain or specifically the BMP-4 protein binding domain, or a peptide corresponding to a TGF- ⁇ -like protein epitope or a BMP-4 protein epitope may be used to produce both polyclonal and monoclonal antibodies to themselves in a variety of cellular media, by such well known techniques as immunization of rabbit using Complete and Incomplete Freund's Adjuvant and the hybridoma technique utilizing, for example, fused mouse spleen lymphocytes and myeloma cells, respectively.
  • such proteins are conjugated to a carrier molecule, as described above.
  • the present invention contemplates an alternative method for identifying specific binding compounds of the binding domain or the region containing a biologically active region using various screening assays known in the art.
  • Any screening technique known in the art can be used to screen for TGF- ⁇ -like or BMP-4 binding antagonists.
  • the present invention contemplates screens for small molecule ligands or ligand analogs and mimics, as well as screens for natural ligands that bind to and antagonize TGF- ⁇ -like proteins or BMP-4 activates in vivo.
  • TGF- ⁇ -like protein or BMP-4 binding domain Knowledge of the primary sequence of the TGF- ⁇ -like protein or BMP-4 binding domain, and the similarity of that sequence with proteins of known function, can provide an initial clue as the inhibitors or antagonists of the protein. Identification and screening of antagonists is further facilitated by determining structural features of the protein, e g. , using X-ray crystallography, neutron diffraction, nuclear magnetic resonance spectrometry, and other techniques for structure determination These techniques provide for the rational design or identification of agonists and antagonists.
  • the screening can be performed directly using peptides corresponding to the receptor binding domain.
  • chimeric proteins which contain the binding domain may be used, as such proteins will contain the element specifically under investigation.
  • the reagents that contain the TGF- ⁇ -like protein or BMP-4 receptor binding domain can be labeled for use in the screening assays.
  • the compound may be directly labeled.
  • a labeled secondary reagent may be used to detect binding of the compound to a solid phase support containing a binding molecule of interest. Binding may be detected by in situ formation of a chromophore by an enzyme label. Suitable enzymes include, but are not limited to, alkaline phosphatase and horseradish peroxidase.
  • labels for use in the invention include colored latex beads, magnetic beads, fluorescent labels (e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, Lucifer Yellow, AMCA blue, free or chelated lanthanide series salts, especially Eu 3+ , to name a few fluorophores), chemiluminescent molecules, radio-isotopes, or magnetic resonance imaging labels.
  • fluorescent labels e.g., fluorescein isothiocyanate (FITC), phycoerythrin (PE), Texas red (TR), rhodamine, Lucifer Yellow, AMCA blue, free or chelated lanthanide series salts, especially Eu 3+ , to name a few fluorophores
  • chemiluminescent molecules chemiluminescent molecules
  • radio-isotopes or magnetic resonance imaging labels.
  • the diagnostic method of the present invention comprises examining a cellular sample or medium by means of an assay including an effective amount of a reagent that specifically binds to a TGF- ⁇ -like or BMP-4 protein.
  • a reagent is an antibody, preferably an affinity-purified polyclonal antibody, and more preferably a mAb.
  • the anti-BMP-4 antibody molecules used herein be in the form of Fab, Fab', F(ab') 2 or F(v) portions or whole antibody molecules.
  • patients capable of benefiting from this method include those suffering from wounds, burns, tumor derived from neural tissue or other like pathological derangement. Methods for determining and optimizing the ability of anti-BMP-4 antibodies to assist in the examination of the target cells are all well-known in the art.
  • a subject therapeutic composition includes, in admixture, a pharmaceutically acceptable excipient (carrier) and one or more agonists or antagonists of a TGF- ⁇ -hke protein, or specifically BMP-4, e.g. , a molecule that specifically interacts with the receptor binding domain of a TGF- ⁇ -like or BMP-4 protein, as described herein as an active ingredient.
  • a pharmaceutically acceptable excipient carrier
  • BMP-4 e.g. , a molecule that specifically interacts with the receptor binding domain of a TGF- ⁇ -like or BMP-4 protein, as described herein as an active ingredient.
  • a gene encoding a mutant TGF- ⁇ -like or BMP-4 protein, whether genomic DNA or cDNA, can be isolated from any source, particularly from a human cDNA or genomic library, and mutated according to standard methods.
  • Specific cDNA sequences encoding BMP proteins are disclosed in U.S. Patent Nos. 5,013,649 and 5, 166,548, which are inco ⁇ orated herein by reference in their entirety.
  • Methods for obtaining the BMP gene are well known in the art, as described above (see, e.g. , Sambrook et al., 1989, supra). Any technique for mutagenesis known in the art can be used, including but not limited to, in vitro site-directed mutagenesis (Hutchinson, C , et al.
  • any animal cell potentially can serve as the nucleic acid source for the molecular cloning of a TGF- ⁇ -like or BMP gene.
  • the DNA may be obtained by standard procedures known in the art from cloned DNA (e.g , a DNA "library”), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell (See, for example, Sambrook et al. , 1989, supra; Glover, D.M (ed ), 1985.
  • Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will not contain intron sequences. Whatever the source, the gene should be molecularly cloned into a suitable vector for propagation of the gene.
  • the nucleotide sequence coding for a mutant TGF- ⁇ -like or BMP-4 protein can be inserted into an appropriate expression vector, i.e. , a vector which contains the necessary elements for the transcription and translation of the inserted protein- coding sequence. Such elements are termed herein "promoters. "
  • promoter a vector which contains the necessary elements for the transcription and translation of the inserted protein- coding sequence.
  • the nucleic acid encoding the mutant TGF- ⁇ -like or BMP-4 protein of the invention is operatively associated with a promoter in an expression vector of the invention. Both cDNA and genomic sequences can be cloned and expressed under control of such regulatory sequences.
  • An expression vector also preferably includes a replication origin.
  • the necessary transcriptional and translational signals can be provided on a recombinant expression vector, or they may be supplied by the native gene encoding a TGF- ⁇ -like protein or BMP-4 and/or its flanking regions.
  • a chimeric TGF- ⁇ -like or BMP-4 protein or mutant TGF- ⁇ -like or BMP-4 protein can be prepared, e.g. , a glutathione-S-transferase (GST) fusion protein, a maltose-binding (MBP) protein fusion protein, or a poly- histidine-tagged fusion protein, for expression in bacteria.
  • GST glutathione-S-transferase
  • MBP maltose-binding
  • poly- histidine-tagged fusion protein for expression in bacteria.
  • GST binds glutathione conjugated to a solid support matrix
  • MBP binds to a maltose matrix
  • the fusion protein can be eluted from the specific matrix with appropriate buffers, or by treating with a protease specific for a cleavage site usually engineered between the TGF- ⁇ -like or BMP-4 polypeptide and the fusion partner (e.g. , GST, MBP. or poly-His).
  • the present invention contemplates fusions between a domain from one TGF- ⁇ -like or BMP-4 protein in the site of the corresponding domain of a second TGF- ⁇ -like or BMP-4 protein.
  • Potential host-vector systems include but are not limited to mammalian cell systems infected with virus (e.g. , vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (e.g.
  • baculovirus containing yeast vectors
  • bacteria transformed with bacteriophage DNA, plasmid DNA, or cosmid DNA.
  • the expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used.
  • a recombinant mutant or chimeric TGF- ⁇ -like protein or BMP-4 of the invention, or functional fragment, derivative or analog thereof, may be expressed chromosomally, after integration of the protein coding sequence by recombination.
  • any of a number of amplification systems may be used to achieve high levels of stable gene expression (See Sambrook et al. , 1989, supra).
  • the cell into which the recombinant vector comprising the nucleic acid encoding the mutant or chimeric TGF- ⁇ -like protein or BMP-4 is cultured in an appropriate cell culture medium under conditions that provide for expression of the protein by the cell.
  • Any of the methods previously described for the insertion of DNA fragments into a cloning vector may be used to construct expression vectors containing a gene consisting of appropriate transcriptional /translational control signals and the protein coding sequences. These methods may include in vitro recombinant DNA and synthetic techniques and in vivo recombination (genetic recombination).
  • Promoters which may be used to control gene expression include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, 1981 , Nature 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, Cell 22:181-797), the he ⁇ es thymidine kinase promoter (Wagner et al. , 1981 , Proc. Natl. Acad. Sci. U.S.A.
  • prokaryotic expression vectors such as the ⁇ -lactamase promoter (Villa-Kamaroff, et al. , 1978, Proc. Natl. Acad. Sci. U.S.A. 75:3727-3731), or the tac promoter (DeBoer, et al., 1983, Proc. Natl. Acad. Sci. U.S.A.
  • Vectors are introduced into the desired host cells by methods known in the art, e.g. , transfection, electroporation, microinjection, transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, lipofection (lysosome fusion), use of a gene gun, or a DNA vector transporter (see, e.g. , Wu et al. , 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263: 14621-14624; Hartmut et al. , Canadian Patent Application No. 2,012,311 , filed March 15, 1990).
  • a gene encoding a mutant TGF- ⁇ -like or BMP-4 protein is introduced in vivo in a viral vector.
  • viral vectors include an attenuated or defective DNA virus, such as but not limited to he ⁇ es simplex virus (HSV), papillomavirus, Epstein Barr virus (EBV), adenovirus, adeno-associated virus (AAV), and the like.
  • HSV he ⁇ es simplex virus
  • EBV Epstein Barr virus
  • AAV adeno-associated virus
  • Defective viruses which entirely or almost entirely lack viral genes, are preferred. Defective virus is not infective after introduction into a cell.
  • Use of defective viral vectors allows for administration to cells in a specific. localized area, without concern that the vector can infect other cells. Thus, a particular locus, e.g.
  • the organ implicated in the rejection episode can be specifically targeted with the vector.
  • particular vectors include, but are not limited to, a defective herpes virus 1 (HSV1) vector (Kaplitt et al. , 1991 , Molec. Cell. Neurosci. 2:320-330), an attenuated adenovirus vector, such as the vector described by Stratford-Perricaudet et al. (1992, J. Clin. Invest. 90:626- 630), and a defective adeno-associated virus vector (Samulski et al. , 1987, J. Virol. 61 :3096-3101 ; Samulski et al., 1989, J. Virol. 63:3822-3828).
  • HSV1 herpes virus 1
  • the vector can be introduced in vivo by lipofection.
  • liposomes for encapsulation and transfection of nucleic acids in vitro.
  • Synthetic cationic lipids designed to limit the difficulties and dangers encountered with liposome mediated transfection can be used to prepare liposomes for in vivo transfection of a gene encoding a protein (Feigner, et. al. , 1987, Proc. Natl. Acad. Sci. U.S.A. 84:7413-7417; see Mackey, et al. , 1988, Proc. Natl. Acad. Sci. U.S.A. 85:8027-8031)).
  • cationic lipids may promote encapsulation of negatively charged nucleic acids, and also promote fusion with negatively charged cell membranes (Feigner and Ringold, 1989, Science 337:387-388).
  • lipofection to introduce exogenous genes into the specific organs in vivo has certain practical advantages.
  • Molecular targeting of liposomes to specific cells represents one area of benefit. It is clear that directing transfection to particular cell types would be particularly advantageous in a tissue with cellular heterogeneity, such as pancreas, liver, kidney, and the brain.
  • Lipids may be chemically coupled to other molecules for the purpose of targeting (see Mackey, et. al. , 1988, supra).
  • Targeted peptides e.g. , hormones or neurotransmitters, and proteins such as antibodies, or non- peptide molecules could be coupled to liposomes chemically.
  • naked DNA vectors for gene therapy can be introduced into the desired host cells by methods known in the art, e.g. , transfection, electroporation, microinjection. transduction, cell fusion, DEAE dextran, calcium phosphate precipitation, use of a gene gun, or use of a DNA vector transporter (see, e.g. , Wu et al. , 1992, J. Biol. Chem. 267:963-967; Wu and Wu, 1988, J. Biol. Chem. 263: 14621- 14624; Hartmut et al. , Canadian Patent Application No. 2,012,31 1 , filed March 15, 1990).
  • compositions which contain polypeptides, analogs or active fragments as active ingredients are well understood in the art.
  • such compositions are prepared as injectables, either as liquid solutions or suspensions, however, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
  • the preparation can also be emulsified.
  • the active therapeutic ingredient is often mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
  • the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents which enhance the effectiveness of the active ingredient.
  • a polypeptide, analog or active fragment can be formulated into the therapeutic composition as neutralized pharmaceutically acceptable salt forms.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide or antibody molecule) and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed from the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • the therapeutic polypeptide-, analog- or active fragment-containing compositions are conventionally administered intravenously, as by injection of a unit dose, for example.
  • unit dose when used in reference to a therapeutic composition of the present invention refers to physically discrete units suitable as unitary dosage for humans, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent; i.e. , carrier, or vehicle.
  • compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount.
  • the quantity to be administered depends on the subject to be treated, capacity of the subject's immune system to utilize the active ingredient, and degree of inhibition or neutralization of epidermal induction or neuralization inhibition desired. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are peculiar to each individual. However, suitable dosages may range from about 0. 1 to 20, preferably about 0.5 to about 10, and more preferably one to several, milligrams of active ingredient per kilogram body weight of individual per day and depend on the route of administration. Suitable regimes for initial administration and booster shots are also variable, but are typified by an initial administration followed by repeated doses at one or more hour intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations of ten nanomolar to ten micromolar in the blood are contemplated.
  • the therapeutic compositions may further include an effective amount of the factor/factor synthesis promoter antagonist or analog thereof, and one or more of the following active ingredients: an antibiotic, a steroid.
  • active ingredients an antibiotic, a steroid.
  • Exemplary formulations are well known in the art, e.g. , as disclosed in International Patent Publication WO 93/19179.
  • an assay useful and contemplated in accordance with the present invention is known as a "cis/trans” assay. Briefly, this assay employs two genetic constructs, one of which is typically a plasmid that continually expresses a particular receptor of interest when transfected into an appropriate cell line, and the second of which is a plasmid that expresses a reporter such as luciferase, under the control of a receptor /ligand complex.
  • one of the plasmids would be a construct that results in expression of the receptor in the chosen cell line, while the second plasmid would possess a promoter linked to the luciferase gene in which the response element to the particular receptor is inserted.
  • the compound under test is an agonist for the receptor
  • the ligand will complex with the receptor, and the resulting complex will bind the response element and initiate transcription of the luciferase gene.
  • the resulting chemiluminescence is then measured photometrically, and dose response curves are obtained and compared to those of known ligands.
  • the foregoing protocol is described in detail in U.S. Patent No. 4,981 ,784 and PCT International Publication No. WO 88/03168, for which pu ⁇ ose the artisan is referred.
  • kits suitable for use by a medical specialist may be prepared to determine the presence or absence of predetermined transcriptional activity or predetermined transcriptional activity capability in suspected target cells, as set forth above.
  • one class of such kits will contain at least a reagent capable of specifically binding to the TGF- ⁇ -like or BMP-4 protein, and means for detecting binding of the reagent to a TGF- ⁇ -like or BMP-4 protein.
  • a reagent is an antibody.
  • Means for detecting binding may be a label on the antibody (labels have been described above), or a label on a TGF- ⁇ -like or BMP-4 protein or fragment thereof.
  • the kits may also contain peripheral reagents such as buffers, stabilizers, etc.
  • the present invention begins with the observation that Xenopus ectoderm cultured in dispersion during early gastrula stages forms neural tissue. Cells dispersed for three hours or more, whether subsequently reaggregated or not, express the general neural marker NCAM at neurula stages.
  • the present results confirm those of (1) Grunz, who found neural structures in animal caps subjected to prolonged dissociation; (2) Sato and Sargent, who reported NCAM expression in disaggregated whole embryos; and (3) Godsave and Slack, who showed that cultures of individual animal pole blastomeres often gave rise to neurons.
  • epidermalizing signals appear to be produced and secreted by the cells themselves during gastrula stages.
  • epidermal specification of the ectoderm formally resembles the class of phenomena grouped under the term "community effect").
  • the present invention demonstrates that the soluble growth factor BMP-4 can induce epidermis in dispersed cells and suppress auto-neural ization. Ectodermal cells exposed to the BMP-4 express epidermal keratin and NCAM expression is suppressed. BMP-4 can exert this effect at low concentrations, below those needed for other reported activities of this protein. This is the first report of epidermal induction in vertebrates by a defined factor.
  • BMP-4 can induce epidermis, and recent work establishes that it meets another crucial test: it is expressed at the appropriate time and place.
  • In situ hybridization carried out by Fainsod et al and by Brivanlou and Thomsen, shows that BMP-4 RNA is present in the entire animal cap at the start of gastrulation, as well as in ventral and lateral marginal zone. At later stages, the transcript disappears from the portion of the ectoderm that becomes the neural plate.
  • the pattern of BMP-4 transcription is consistent with a function in the induction of epidermis and the suppression of neural development.
  • the present invention demonstrates that interference with TGF- ⁇ signaling in a mammalian embryonic cell line leads to the specification of neural cells, indicating that the molecular strategy behind neural determination is conserved throughout vertebrate evolution.
  • Disruption of signaling by stable expression of a truncated, dominant-negative, Xenopus activin type II receptor ( ⁇ lXARlmyc) can induce neurons in P19 cells.
  • ⁇ lXARlmyc truncated, dominant-negative, Xenopus activin type II receptor
  • BMP4 can inhibit the RA induced neural differentiation of P19 cells and is capable of inducing epithelial cells in P19 cultures as assessed by keratin expression.
  • the present invention also demonstrates that a related protein, activin, cannot epidermalize in the dispersed cell assay.
  • a related protein, activin cannot epidermalize in the dispersed cell assay.
  • BMP-7 deserves special attention, since it too is expressed in the gastrula ectoderm.
  • the present invention also demonstrates that, as in Xenopus embryos and embryonic explants, a truncated activin type II receptor neuralizes PI 9 cells; and that the mechanism previously proposed, in which inhibition of TGF- ⁇ signaling is required for neural differentiation, is evolutionarily conserved from amphibians to mammals.
  • the truncated activin receptor induces neurons in the absence of mesoderm induction (Hemmati-Brivanlou and Melton, 1994).
  • mesoderm induction Hemmati-Brivanlou and Melton, 1994.
  • neural specification in the apparent absence of mesoderm was observed since both skeletal and cardiac myosin antigens were not expressed in the transfected cells.
  • Assessing the lack of mesoderm in this cell line is complicated, however, by the fact that the brachyury gene, a mesodermal marker, is expressed at low levels in undifferentiated PI 9 cells.
  • Brachyury is induced when P19 cells undergo mesodermal differentiation in response to DMSO but not during neural differentiation by RA (Vidricaire et al. , 1994).
  • the truncated type II activin receptor inhibits all BMPs and activins tested so far (Hemmati-Brivanlou and Thomsen, 1995; Kessler and Melton, 1995; Schulte-Merker et al. , 1994). Thus any of these factors can be a potential candidate for the endogenous neural inhibitor.
  • Recent knockout experiments in the mouse has helped in providing clues about the factors acting in the early embryo. Elimination of both activin A and B from the embryo has no consequence in the establishment of ectodermal patterning and neural fate specification (Matzuk et al. , 1995b; Vassalli et al.
  • mice deficient in the type II activin receptor, ActRcII have normal neural development and ectodermal patterning (Matzuk et al., 1995a).
  • parallel signaling from additional activin type II receptors cannot be excluded.
  • the knockouts of BMP4 ligand or the type I receptor (BMPR) results in embryonic death at gastrulation (Mishina et al.
  • BMP4 is the vertebrate homolog of the Drosophila TGF- ⁇ family member dpp
  • chordin is the vertebrate counte ⁇ art of short gastrulation (sog).
  • BMP4 and chordin or dpp and sog are responsible for ectodermal patterning and the establishment of the neural and epidermal fate.
  • the present invention indicates that the same molecular mechanisms are operating during arthropod, amphibian and mammalian development and that the conservation of the molecular pathway involved in ectodermal cell fate decision extends beyond arthropods and amphibians to include amniotes.
  • neuralization appears to involve inhibition of the epidermal inducer. Since simple dispersion in the absence of added factors results not only in the repression of epidermal differentiation but in the formation of neural tissue, such a block is apparently sufficient as well as necessary for neural specification.
  • Two experimental treatments known to neuralize animal caps plausibly act by this route: (1) injection of RNAs encoding a truncated, dominant-negative form of the activin receptor; and (2) follistatin. Although these interventions were designed to interfere with activin signalling, both may act against BMP-4. It has recently been demonstrated that the truncated activin receptor can block the induction of ventral mesoderm by BMP-4 in intact animal caps, and the present invention demonstrates that it can also prevent epidermalization by BMP-4 in dispersed cells.
  • Follistatin is unable to block BMP-4 in the assay of the present invention, even at quite high concentrations. It may be that follistatin is not an endogenous neural inducer, perhaps serving instead to limit the spread of mesoderm induction by activin. Injected follistatin RNA, may neuralize the animal cap by blocking an earlier activin-requiring process necessary for later epidermal specification. This may explain why it has not been shown that follistatin can neuralize when supplied at gastrula stages, either as a purified protein or by injecting a plasmid containing follistatin driven by a gastrula-stage promotor (data not shown).
  • follistatin may in fact block BMP-4 signalling in the embryo although it is unable to do so in the context of dispersed ectoderm. This could be, for example, because follistatin-BMP-4 interaction requires a third player, perhaps activin.
  • BMP-4 may act in the ectoderm to suppress a so-called default fate. When this signalling is blocked, by injection of a dominant-negative receptor, an unsuspected dorsal specification is revealed. Thus it appears that BMP-4 may play a similar role in the marginal zone and the animal cap.
  • FIG. 1 A shows that when late blastula animal caps are disaggregated and cultured in dispersion for several hours before being allowed to reaggregate, the general neural marker NCAM is subsequently expressed. Furthermore, the epidermal keratin XK81 , strongly expressed in intact animal caps, is turned off by prolonged dispersion.
  • NCAM expression by dispersed animal cap cells does not require that the ectoderm be reaggregated (Figure IB). This implies that neural specification does not result from cell-cell interactions taking place after the period of dispersal, as it would, for example, if dispersal somehow rendered some cells capable of neural lzing their neighbors.
  • Activin cannot restore dispersed ectoderm to an epidermal fate.
  • activin had no effect: after reaggregation and culture, cells exposed to these levels expressed NCAM and turned off the epidermal marker, just as in the absence of activin.
  • higher concentrations of activin induced the dispersed ectoderm to form mesoderm, revealed here by expression of the mesodermal marker Xbra. (Even higher doses of activin would have prompted the expression of more dorso-ante ⁇ or mesodermal markers.) Both NCAM and epidermal keratin are turned off in these mesodermal lzed reaggregates. At no concentration ot activin was epidermis formed.
  • activin is not able to substitute for an endogenous epidermal inducer inactivated by the dispersal of gastrula ectoderm. Activin is able to inhibit the neuralization of dispersed cells, but only by inducing mesoderm, not epidermis.
  • the dominant-negative activin receptor but not follistatin protein, can block epidermal induction by BMP-4.
  • Figure 4A demonstrates that the truncated receptor can block epidermalization by BMP-4: cells from uninjected caps are induced to express epidermal keratin, but those from injected embryos continue to express NCAM after exposure to BMP-4 protein. As expected from previous work, intact caps containing truncated receptor were neuralized, and mesoderm induction by activin was inhibited, although only partially at the concentrations used in this experiment ( Figure 4B).
  • follistatin was examined using soluble protein rather than injected RNA, since protein produced by injected cells would be diluted by dispersal. Late blastula ectoderm was dispersed as before and cultured for four hours in media containing BMP-4, BMP-4 and follistatin protein, or neither factor. As Figure 5A shows, follistatin is apparently unable to block BMP-4 action in this assay, although in accompanying experiments the same preparation of follistatin is a potent inhibitor of activin (Figure 5B).
  • follistatin can neither prevent the induction of epidermal keratin nor restore NCAM expression in ectoderm exposed to BMP-4 during dispersed culture. In other experiments, even a 50-fold molar excess of follistatin does not prevent induction of epidermis by BMP-4.
  • PI 9 is a pluripotent mouse embryonic carcinoma cell line capable of differentiating into many cell types. P19 cells, when injected into mouse blastocysts, can contribute to many different tissue types indicating that these cells maintain the capacity to differentiate in response to many developmental signals (Rolich and McBurney, 1982). While undifferentiated PI 9 cells can be stably maintained in culture, various agents can induce differentiation of these cells.
  • retinoic acid > lOOnM
  • DMSO 0.8-1.0%
  • mesodermal cell types such as cardiac and skeletal muscle
  • Neurons resulting from retinoic acid (RA) induced differentiation maintain many features of normal neurons, such as a neural morphology and the ability to develop functional synapses (Morassutti et al. , 1994). In addition.
  • RA induced neuralization of PI 9 cells is accompanied by the induction of several factors, such as Mash-1 , Wnt-1 and mNotch, associated with neural development in vivo (reviewed in Bain et al., 1994). These factors appear to follow a temporal pattern during neural differentiation similar to that observed in the mouse embryo. These results support that the basic mechanisms of neural differentiation are intact in these cells and that PI 9 cells provide a convenient model for the study of early mammalian neural development.
  • a Dominant-Negative Activin Receptor Induces P19 Cells to Differentiate into Neurons:
  • Xenopus activin type II receptor ( ⁇ lXARl) was cloned into an expression plasmid, pcDNA3, in which expression is under the control of a CMV promoter.
  • the Xenopus receptor was chosen since its inhibitory functions have been well characterized in the context of a developmental system (Hemmati-Brivanlou and Melton, 1992; Hemmati-Brivanlou and Melton, 1994).
  • activin receptors are capable of functioning across species (Suzuki et al. , 1994).
  • an epitope tag which contains 10 amino acids from the human c-myc gene, was fused to the carboxyl terminus of the truncated receptor. This epitope did not interfere with the function of the receptor in the context of Xenopus ectodermal explants (data not shown) and can be recognized by the monoclonal antibody, clone 9E10, without species cross reactivity with endogenous myc proteins (Evan et al. , 1985).
  • the truncated activin receptor was stably introduced into the embryonic carcinoma cell line, P19 using a selectable marker, the neomycin resistance gene within the plasmid.
  • the level of staining for both the myc antibody and the neural specific antibodies is different from cell to cell. Some cells display only low levels of expression while other cells have bright, punctate labeling. The cells displaying a neural phenotype as assessed by NF-200 staining are those that express the highest amount of the truncated receptor, as visualized with the anti-myc antibody ( Figure 7B). While much of the myc epitope is observed in the cell bodies, some labeling can be seen in the axons, suggesting that the truncated receptor is expressed throughout the cell membrane. The expression of mesodermal markers such as skeletal and cardiac myosin in
  • the percentage of cells displaying the neural antigen NF-160 increased as the cells reached confluence.
  • RA it has been noted that cell cell contact is required for the generation of neural fate (Schmidt et al. , 1992).
  • a time course was used in which the cells were plated at low density and cultured for several days without re-plating. No neurons were observed when cells were plated at low density, as assessed by the expression of the NF-160 antigen. After 4 days in culture, at which time the cells were nearing confluence, some cells (less than 0.1 %) began to display a neural phenotype.
  • BMP4 activity can be antagonized by the ⁇ lXARl , making this factor a good candidate for a neural inhibitor (Hemmati-Brivanlou and Thomsen, 1995). In the dorsal side the activity or expression of BMP4 must be inhibited for the neural fate to be unveiled. Because of the observations made in the frog embryo, the next question was whether BMP4 protein can display the same type of activity in the context of the mouse embryonic cell line. Toward this aim, P19 cells were grown on solid surfaces in the presence of RA and pure human BMP4 recombinant protein. Cultures were then examined for neural differentiation using the NF-160 antibody.
  • Figure 9E shows that PI 9 cells grown in the presence of 0.5mM RA showed extensive neural differentiation.
  • Figure 9C shows that BMP4 alone even high concentrations (3.6nM) had no neural inducing ability.
  • BMP4 protein completely blocks neural induction by RA ( Figure 9G and I). This inhibition, as manifested by both lower number of cells with NF-160 positive staining cells and lack of neural phenotype, is observed even when BMP4 concentrations as low as 0.36nM are used to challenge the inducing activity of RA, pointing to a physiological effect. The inhibition followed a dose response effect and was even more extensive in the presence of higher concentration of the BMP4 protein (Figure 91).
  • the amount of BMP4 required to inhibit RA induction is comparable to both the doses required for activin inhibition of RA induced P19 cells (Hashimoto et al. , 1990) and to the amount of BMP4 protein required to achieve the same effect in the context of Xenopus ectodermal explants (Wilson and
  • BMP4 inhibits neural differentiation and induces epidermis in ectodermal cells, suggesting that these two activities represent a single action. Since BMP4 can inhibit neural specification in P19 cells, the question was whether epidermis was induced at the same time. Since no early epidermal specific marker has been described in these cells or in the mouse embryo, an antibody mixture recognizing several keratins that are markers for epithelial cells including epidermis was used (Kopan and Fuchs, 1989; Moll et al. , 1982). This mixture contains antibodies against keratins 1 , 4, 5, 6, 8, 10, 13, 18 and 19 (Sigma).
  • P19 cells were obtained from ATCC and cultured according to Rudnicki and McBurney (Rudnicki and McBurney, 1987). Cells were cultured in ⁇ -MEM with 7.5 % bovine calf serum and 2.5% fetal calf serum.
  • RA retinoic acid
  • BMP4 BMP4
  • PI 9 cells were grown in suspension in bacterial plates at an initial density of 5 x 10 5 cells/ml in media with or without factors. Media was replaced every 2 days followed by plating after 4 days onto a solid surface in the absence of factors.
  • Human BMP4 was a gift from Genetics Institute Inc.
  • P19 cells were transfected on 100mm plates with plasmid DNA (lOmg) using calcium precipitate-mediated transfection (Wigler et al. , 1979). Colonies were selected and maintained in media supplemented with 350mg/ml geneticin (Gibco/BRL). Approximately 40 colonies transfected with the myc-tagged truncated activin receptor and 10 colonies transfected with pcDNA3 were isolated. Early passage cells were used in all experiments.
  • NF-160 (clone NN18) monoclonal antibody and NF-200 polyclonal antibody were obtained from Sigma and the myc monoclonal antibody, clone 9E10, was obtained from Oncogene Science (Evan et al. , 1985).
  • the keratin antibody (Sigma, C 2562) contains a mixture of monoclonal antibodies and will react with keratins 1 , 4, 5, 6, 8, 10, 13, 18 and 19. All secondary antibodies, Texas red conjugated, goat, anti-mouse IgG, fluorescein conjugated, goat, anti-mouse IgG and fluorescein conjugated, goat, anti-rabbit IgG were obtained from Jackson Laboratories.
  • Cells were plated and grown on gelatin coated, 8-well, Permanox, chamber slides (LabTek). At the indicated time, cells were washed with PBS, fixed for 10 min. at room temperature in 4 % paraformaldehyde made in PBS, washed twice with PBS, permeablized with methanol for 2 min. at room temperature and washed several times with PBS. Prior to addition of antibody, cells were preincubated in 10% goat serum in PBT (PBS with 2mg/ml BSA and 0.1 % triton-X-100) for lh at room temperature. For primary antibodies, cells were incubated overnight at 4"C in 10% goat serum and PBT followed by 4 washes in PBT.
  • the primary antibodies were used at the following dilutions: NF-160 at 1 :80, NF-200 at 1 :200 and keratin at 1 : 100.
  • the 9E10 antibody was used at a final concentration of 2mg/ml.
  • Secondary antibodies at a 1 :200 dilution were incubated for lh at room temperature in 10% goat serum and PBT. Following the secondary antibody, cells were washed 4-5 times with PBT over 20 min. at room temperature.
  • Hoechst staining cells were incubated in Hoechst (1 mg/ml in PBS) for 5 min. at room temperature followed by two PBS washes.
  • a Zeiss Axioplan microscope was used with the appropriate filters. Figure 7 was photographed using a Zeiss confocal microscope.
  • NF-160 antigen For quantitation of neural phenotype, as detected by the NF-160 was calculated by plating, cells on chamber slides as described above. Total number of cells in each field was assessed by using the Hoechst nuclear staining and neural cells were assessed by the expression of the NF-160 antigen.
  • Bmpr encodes a type I bone mo ⁇ hogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes and Development 15:3027-3037. Moll, R., Franke, W. W. , and Schiller, D. L. (1982). The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24. Morassutti, D. J. , Staines, W. A. , Magnuson, D. S. K. , Marshall, K. C , and McBurney, M. W. (1994).
  • Xenopus chordin A novel dorsalizing factor activated by organizer-specific homeobox genes. Cell 79, 779-790. Sato, S. M. , and Sargent, T. D. (1989). Development of neural inducing capacity in dissociated Xenopus Embryos. Dev. Biol. 134:263-266.
  • Osteogenic protein- 1 binds to activin type II receptors and induces certain activin-like effects. J. Cell Biol. 130, 217-26.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à un procédé de suppression de l'autoneuralisation et d'induction de l'épiderme à l'aide d'un facteur de croissance peptidique qui est un produit génique d'un membre de la famille de gènes TGF-β. Ce procédé favorise la cicatrisation et s'utilise dans la technique de culture de la peau et le traitement des tumeurs dérivées de tissus neuraux.
PCT/US1996/004326 1995-03-29 1996-03-29 Facteur de croissance peptidique ayant une activite induisant l'epiderme WO1996030038A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP96910644A EP0820298A1 (fr) 1995-03-29 1996-03-29 Facteur de croissance peptidique ayant une activite induisant l'epiderme
AU53783/96A AU5378396A (en) 1995-03-29 1996-03-29 Peptide growth factor having epidermal inducing activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41304795A 1995-03-29 1995-03-29
US08/413,047 1995-03-29
US08/622,860 1996-03-29

Publications (1)

Publication Number Publication Date
WO1996030038A1 true WO1996030038A1 (fr) 1996-10-03

Family

ID=23635597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/004326 WO1996030038A1 (fr) 1995-03-29 1996-03-29 Facteur de croissance peptidique ayant une activite induisant l'epiderme

Country Status (1)

Country Link
WO (1) WO1996030038A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054572A1 (fr) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Procedes pour evaluer la morphogenese des tissus et leur activite
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2020106074A1 (fr) 2018-11-23 2020-05-28 (주)메디코스바이오텍 Composition pharmaceutique pour le traitement de coupures

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009697A1 (fr) * 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. UTILISATION EN OSTEOPATHIE D'UNE PROTEINE MORPHOGENETIQUE D'ORIGINE OSSEUSE ASSOCIEE DE MANIERE SYNERGIQUE AVEC DU BETA DE FACTEUR DE CROISSANCE DE TRANSFORMATION (β-FCT).
WO1994003200A1 (fr) * 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Regeneration et reparation du systeme nerveux induites par morphogene
WO1995005846A1 (fr) * 1993-08-26 1995-03-02 Genetics Institute, Inc. Regeneration nerveuse utilisant des proteines morphogenetiques osseuses chez l'homme

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992009697A1 (fr) * 1990-11-30 1992-06-11 Celtrix Laboratories, Inc. UTILISATION EN OSTEOPATHIE D'UNE PROTEINE MORPHOGENETIQUE D'ORIGINE OSSEUSE ASSOCIEE DE MANIERE SYNERGIQUE AVEC DU BETA DE FACTEUR DE CROISSANCE DE TRANSFORMATION (β-FCT).
WO1994003200A1 (fr) * 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Regeneration et reparation du systeme nerveux induites par morphogene
WO1995005846A1 (fr) * 1993-08-26 1995-03-02 Genetics Institute, Inc. Regeneration nerveuse utilisant des proteines morphogenetiques osseuses chez l'homme

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HARLAND, RICHARD M.: "The transforming growth factor.beta. family and induction of the vertebrate mesoderm: bone morphogenetic proteins are ventral inducers", PROC. NATL. ACAD. SCI. U. S. A. (1994), 91(22), 10243-6, 1994, XP002011029 *
HAWLEY S H B ET AL: "Disruption of BMP signals in embryonic Xenopus ectoderm leads to direct neural induction.", GENES & DEVELOPMENT 9 (23). 1995. 2923-2935, XP000578233 *
HEMMATI-BRIVANLOU A ET AL: "Ventral Mesodermal Patterning in Xenopus Embryos: Expression Patterns and Activities of BMP -2 and BMP -4.", DEVELOPMENTAL GENETICS 17 (1). 1995. 78-89, XP000578234 *
SASAI Y ET AL: "Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus.", NATURE (LONDON) 376 (6538). 1995. 333-336, XP002011031 *
WILSON P A ET AL: "Induction of epidermis and inhibition of neural fate by Bmp -4.", NATURE (LONDON) 376 (6538). 1995. 331-333, XP002011030 *
WINNIER G ET AL: "Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse.", GENES & DEVELOPMENT 9 (17). 1995. 2105-2116, XP000578232 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054572A1 (fr) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Procedes pour evaluer la morphogenese des tissus et leur activite
EP1988395A1 (fr) * 1997-05-30 2008-11-05 Curis, Inc. Procédés d'évaluation de la morphogénèse de tissus et activité
EP2309261A1 (fr) * 1997-05-30 2011-04-13 Stryker Corporation Procédés d'évaluation de la morphogénèse de tissus et activité
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
WO2020106074A1 (fr) 2018-11-23 2020-05-28 (주)메디코스바이오텍 Composition pharmaceutique pour le traitement de coupures

Similar Documents

Publication Publication Date Title
Vogel et al. Involvement of FGF-8 in initiation, outgrowth and patterning of the vertebrate limb
Mayor et al. Role of fgf andnogginin neural crest induction
Hunter et al. The extracellular matrix component WIF-1 is expressed during, and can modulate, retinal development
Noden Spatial integration among cells forming the cranial peripheral nervous system
Mummery et al. Expression of transforming growth factor β2 during the differentiation of murine embryonal carcinoma and embryonic stem cells
US20050186628A1 (en) Dorsalin-1 polypeptide and uses thereof
Tucker et al. Teneurin‐2 is expressed in tissues that regulate limb and somite pattern formation and is induced in vitro and in situ by FGF8
Kinkl et al. Fibroblast growth factor receptor (FGFR) and candidate signaling molecule distribution within rat and human retina
JP2009142287A (ja) フラズルドヌクレオチド配列、発現生成物、組成物および用途
Van den Eijnden-van Raaij et al. Differential expression of inhibin subunits and follistatin, but not of activin receptor type II, during early murine embryonic development
EP1772514A2 (fr) Manipulation de type de tissu ou d'organe par utilisation de la voie Notch
US5882923A (en) Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth
WO1996030038A1 (fr) Facteur de croissance peptidique ayant une activite induisant l'epiderme
KR102421385B1 (ko) 광수용체세포와 망막색소상피세포의 특성을 동시에 나타내는 망막세포를 포함하는 세포 조성물 및 이의 용도
EP0820298A1 (fr) Facteur de croissance peptidique ayant une activite induisant l'epiderme
Hoodless et al. Inhibitory control of neural differentiation in mammalian cells
Guo Maintenance, differentiation and regulation of multipotent progenitor cells in the olfactory epithelium
Leong The role of bone morphogenetic protein-4 in the developing chick eye
Smith et al. Divergence of smooth muscle target and sympathetic pathway cell phenotypes in the orbit of the developing rat
Weekes Investigating the role of bmp antagonists in vertebrate eye development
Amand Expression and regulation of Pitx genes during vertebrate organogenesis
Dudley Analysis of Bmp7 function during metanephric development
Williams The cellular and molecular changes occurring in the degenerating and regenerating olfactory system
Berliner ERNI: an early response to signals from Hensen's node
Zacharias Lineage-specific functions of the homeodomain transcription factor Pitx2 in eye development

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1996910644

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996910644

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996910644

Country of ref document: EP